Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Trifluridine/Tipiracil + Bevacizumab in mCRC
NCT07071844Phase 2Not yet recruiting
- Sponsor
- GERCOR
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in metastatic colorectal cancer (mCRC), sponsored by GERCOR. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07071844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071844.